Discover and read the best of Twitter Threads about #GastricCancer
Most recents (8)
Science behind the Study:
#GastricCancer is a common and often lethal cancer that, like cervical and liver cancer, can be attributed in large part to an infectious cause.
Full editorial on gastric cancer risk available here: nej.md/3JQQY4v 1/15
#GastricCancer is a common and often lethal cancer that, like cervical and liver cancer, can be attributed in large part to an infectious cause.
Full editorial on gastric cancer risk available here: nej.md/3JQQY4v 1/15
In the case of gastric cancer, the infectious agent is a bacterium, Helicobacter pylori. Until now, hereditary forms of gastric cancer were thought to be limited to a small percentage of CDH1-mutant cases. 2/15 
In this week’s issue of NEJM, Usui et al. provide compelling evidence for a substantial contribution from inherited (germline) variants in nine cancer genes to the risk of gastric cancer. Read the study here: nej.md/40Br5MC 3/15
@TumorBoardTues 1/15 #TumorBoardTuesday #GastricCancer #OncTwitter
Here goes
🎬Starting out with an overall poll Q
When a new advanced GC/GEJ patient presents to your clinic, your institution reflexively tests for which of the following?
Here goes
🎬Starting out with an overall poll Q
When a new advanced GC/GEJ patient presents to your clinic, your institution reflexively tests for which of the following?
@TumorBoardTues 2/15 #TumorBoardTuesday
68y/o with poorly diff gastric cardia adeno, diffuse LAD, +peritoneal mets.
🧬Biomarkers HER2-, PD-L1-, MSS
🧪Pre-screened for trials & FGFR2b-, Claudin18.2+
🔦Enrolls in frontline SPOTLIGHT trial.
❓What is Claudin18.2?
❓What is SPOTLIGHT?
68y/o with poorly diff gastric cardia adeno, diffuse LAD, +peritoneal mets.
🧬Biomarkers HER2-, PD-L1-, MSS
🧪Pre-screened for trials & FGFR2b-, Claudin18.2+
🔦Enrolls in frontline SPOTLIGHT trial.
❓What is Claudin18.2?
❓What is SPOTLIGHT?
@TumorBoardTues 3/15 #TumorBoardTuesday
✨Claudin18.2 (CLDN18.2)✨
Transmembrane protein typically present in tight junctions of gastric mucosal cells, maintains barrier function of gastric mucosa, & prevents leakage of H+ in gastric acid through paracellular pathways.
✨Claudin18.2 (CLDN18.2)✨
Transmembrane protein typically present in tight junctions of gastric mucosal cells, maintains barrier function of gastric mucosa, & prevents leakage of H+ in gastric acid through paracellular pathways.
😳🤯The hour flew by & none of us noticed!!
🙏🏽 @FogacciJoao for bringing the 🇧🇷 flair to #TumorBoardTuesday & #GastricCancer!!
🏆Remember your🆓CME
Look for Case Wrap Up🎀 04/28/22
📅Mark your calendar for 05/10/22 8pm ET when @FlavioRochaMD joins our #VirtualTumorBoard!!
🙏🏽 @FogacciJoao for bringing the 🇧🇷 flair to #TumorBoardTuesday & #GastricCancer!!
🏆Remember your🆓CME
Look for Case Wrap Up🎀 04/28/22
📅Mark your calendar for 05/10/22 8pm ET when @FlavioRochaMD joins our #VirtualTumorBoard!!
Remember #TumorBoardTuesday education goes beyond Twitter - we offer 🆓 CME!!
Pick up your🏆#CME & NOW #MOC(‼️) by answering quick questions regarding a case similar to @FogacciJoao’s‼️
🔗ALL CME: integrityce.com/tbt
🔗 post rationale: bit.ly/3kcIXdv
🇧🇷🎁🇧🇷
Pick up your🏆#CME & NOW #MOC(‼️) by answering quick questions regarding a case similar to @FogacciJoao’s‼️
🔗ALL CME: integrityce.com/tbt
🔗 post rationale: bit.ly/3kcIXdv
🇧🇷🎁🇧🇷
#PostTest Q1️⃣ #CME #TumorBoardTuesday @MPishvaian
🤔Now that @FogacciJoao schooled us through updates on immunotherapy for #GastricCancer, how would you answer these 2 quick ❓
🧬 Which are potentially useful immunotherapy biomarkers in gastric cancer?
🤔Now that @FogacciJoao schooled us through updates on immunotherapy for #GastricCancer, how would you answer these 2 quick ❓
🧬 Which are potentially useful immunotherapy biomarkers in gastric cancer?
🚨 #CME Thursday 🚨
This week at #TumorBoardTuesday @W_Park_MD discussed FGFR inhibitors in #BiliaryTractCancer #CCA...and how to find FGFR fusions!
Check out the questions below, and tap the link to claim your free #CME...and stay tuned for a special edition of case wrap up!
This week at #TumorBoardTuesday @W_Park_MD discussed FGFR inhibitors in #BiliaryTractCancer #CCA...and how to find FGFR fusions!
Check out the questions below, and tap the link to claim your free #CME...and stay tuned for a special edition of case wrap up!
#PostTest Q 1️⃣ #CME #TumorBoardTuesday
👉🏽 ALL CME🔗 integrityce.com/tbt
🤔 What is a molecular biomarker for an FDA approved🎯💊in #Cholangiocarcinoma❓
#OncTwitter #GeneTesting #CCA
👉🏽 ALL CME🔗 integrityce.com/tbt
🤔 What is a molecular biomarker for an FDA approved🎯💊in #Cholangiocarcinoma❓
#OncTwitter #GeneTesting #CCA
#PostTest Q 2️⃣ #CME #TumorBoardTuesday
👉🏽 ALL CME🔗 integrityce.com/tbt
🤔 To detect 🧬 gene rearrangement what is the preferred method❓
#OncTwitter #GeneTesting #CCA
👉🏽 ALL CME🔗 integrityce.com/tbt
🤔 To detect 🧬 gene rearrangement what is the preferred method❓
#OncTwitter #GeneTesting #CCA
Good Morning #GImedTwitter
🌅🌄🌇Whether you are waking up in San Francisco…..or not (Curse you COVID-19😡)
🧑🏫Get ready for 3 packed days of presentations at #GI22
And to get the🧠started, we are going to share our
Top 10 Targeted Therapy Abstracts🎯
#TumorBoardTuesday
🌅🌄🌇Whether you are waking up in San Francisco…..or not (Curse you COVID-19😡)
🧑🏫Get ready for 3 packed days of presentations at #GI22
And to get the🧠started, we are going to share our
Top 10 Targeted Therapy Abstracts🎯
#TumorBoardTuesday
#TumorBoardTuesday
1⃣/
Once again HER2🎯💊is everywhere #GI22
👉The DESTINY trials have been👍4⃣T-DXd
✅DESTINY-CRC01
➡️T Yoshino, et al "RAPID" Abs 119
⏩53 "Group A" HER2+ RASWT CRC pts
⏩ORR 45%, mOS 15.5 mos
👍Even with prior HER2 Tx
😨But GR>=3 AEs in 65% of pts, 9% ILD
1⃣/
Once again HER2🎯💊is everywhere #GI22
👉The DESTINY trials have been👍4⃣T-DXd
✅DESTINY-CRC01
➡️T Yoshino, et al "RAPID" Abs 119
⏩53 "Group A" HER2+ RASWT CRC pts
⏩ORR 45%, mOS 15.5 mos
👍Even with prior HER2 Tx
😨But GR>=3 AEs in 65% of pts, 9% ILD
#TumorBoardTuesday #GI22
2⃣/
✅DESTINY-Gastric 01
➡️K Yamaguchi, et al "RAPID" Abs 242
⏩Randomized Ph II trial of >=2nd line💊
👉T-DXd vs. Physician’s choice (PC) which was Iri or Paclitaxel
⏩mOS 12.5 v 8.9 mos
⏩ORR 51% vs 14%
😨But Grade >= 3 AEs were 86% vs 57%
2⃣/
✅DESTINY-Gastric 01
➡️K Yamaguchi, et al "RAPID" Abs 242
⏩Randomized Ph II trial of >=2nd line💊
👉T-DXd vs. Physician’s choice (PC) which was Iri or Paclitaxel
⏩mOS 12.5 v 8.9 mos
⏩ORR 51% vs 14%
😨But Grade >= 3 AEs were 86% vs 57%
1/10 #TumorBoardTuesday
Thursday Case🎀
This week’s case: pt w #GEA not responding to FLOT w dMMR/MSI. Receives 3 doses of pembrolizumab->pCR!
💡Biomarker-based IO can be v successful, but better biomarkers needed‼️
➡️Explore wrap up below re: deploying IO in #UGI
Thursday Case🎀
This week’s case: pt w #GEA not responding to FLOT w dMMR/MSI. Receives 3 doses of pembrolizumab->pCR!
💡Biomarker-based IO can be v successful, but better biomarkers needed‼️
➡️Explore wrap up below re: deploying IO in #UGI
2/10 #TumorBoardTuesday
👉👉 Don’t forget to pick up your 🆓 #CME credit by answering 2 quick ❓
Here is the post-test 🔗: bit.ly/3EgtZeE
ALL CME 🔗: integrityce.com/tbt
👉👉 Don’t forget to pick up your 🆓 #CME credit by answering 2 quick ❓
Here is the post-test 🔗: bit.ly/3EgtZeE
ALL CME 🔗: integrityce.com/tbt
3/10 #TumorBoardTuesday
Thursday Case🎀
Take🏠messages:
We discussed #GastricCancer & immunotherapy (IO)
✅dMMR/MSI quite common- 8-22% of non-metastatic cases
✅Chemo less effective in dMMR disease, particularly 5-FU
✅High pCR with upfront IO
✅ctDNA may be a key biomarker
Thursday Case🎀
Take🏠messages:
We discussed #GastricCancer & immunotherapy (IO)
✅dMMR/MSI quite common- 8-22% of non-metastatic cases
✅Chemo less effective in dMMR disease, particularly 5-FU
✅High pCR with upfront IO
✅ctDNA may be a key biomarker
1/9 #TumorBoardTuesday
🔬A discussion on EBV+ #GastricCancer-important differences in tx led by @SunnieSKim
➡️Here's the Thursday Case🎀
👉👉Don’t forget to pick up🆓 #CME by answering 2 quick❓
Here's post-test🔗: bit.ly/3yRO1cb
ALL CME🔗: integrityce.com/tbt
🔬A discussion on EBV+ #GastricCancer-important differences in tx led by @SunnieSKim
➡️Here's the Thursday Case🎀
👉👉Don’t forget to pick up🆓 #CME by answering 2 quick❓
Here's post-test🔗: bit.ly/3yRO1cb
ALL CME🔗: integrityce.com/tbt
2/9 #TumorBoardTuesday Thursday Case🎀
Take🏠:
#GastricCancer are NOT all the same; ≈10% EBV+
✅EBV+ likely⬆️PD-L1; exclusive w HER2 mut
✅EBV+ responsive to immunotx
✅Should EBV🧪be standard?
📚We captured as much of @SunnieSKim’s chat as we could:
twitter.com/i/events/14332…
Take🏠:
#GastricCancer are NOT all the same; ≈10% EBV+
✅EBV+ likely⬆️PD-L1; exclusive w HER2 mut
✅EBV+ responsive to immunotx
✅Should EBV🧪be standard?
📚We captured as much of @SunnieSKim’s chat as we could:
twitter.com/i/events/14332…
3/9 #TumorBoardTuesday Thurs Case🎀
@SunnieSKim tweetorial
✅8-10% of GC =EBV+
✅Methyl of viral/host DNA➡️GC
✅⬆️in👨🦰/young pts
✅Diffuse type, lymphoid infiltrate & prox loc
✅🔦: hypoechoic submuc nodule
✅⬆️CD8+ TILs & immune 🧬 (IFN-g)
✅TP53, HER2 changes✖️common in EBV+
@SunnieSKim tweetorial
✅8-10% of GC =EBV+
✅Methyl of viral/host DNA➡️GC
✅⬆️in👨🦰/young pts
✅Diffuse type, lymphoid infiltrate & prox loc
✅🔦: hypoechoic submuc nodule
✅⬆️CD8+ TILs & immune 🧬 (IFN-g)
✅TP53, HER2 changes✖️common in EBV+
#TumorBoardTuesday
That was a super🦸high energy⚡️ @TumorBoardTues case discussion led by @AJacomeMD
🙏for joining
➡️Here is this week's Thursday Case🎀
👉👉Don't forget to pick up your🆓#CME credit by answering these 2 quick❓s
Here's the post-test🔗
integrityce.com/posttest3-23
That was a super🦸high energy⚡️ @TumorBoardTues case discussion led by @AJacomeMD
🙏for joining
➡️Here is this week's Thursday Case🎀
👉👉Don't forget to pick up your🆓#CME credit by answering these 2 quick❓s
Here's the post-test🔗
integrityce.com/posttest3-23
#TumorBoardTuesday
Thursday Case🎀
(Case from 03/23/21)
We had an great discussion about gastric cancer, and FGFR-fusions
We captured as much as we could in this moment:
twitter.com/i/events/13739…
Thursday Case🎀
(Case from 03/23/21)
We had an great discussion about gastric cancer, and FGFR-fusions
We captured as much as we could in this moment:
twitter.com/i/events/13739…
#TumorBoardTuesday
Thursday Case🎀
(Case from 03/23/21)
@AJacomeMD presented a case of a young patient with metastatic gastroesophageal cancer
🔬Poorly-diff adenoca, signet-ring cells, pMMR, HER2-, CPS 0
Most of us would have recommended FOLFOX
Thursday Case🎀
(Case from 03/23/21)
@AJacomeMD presented a case of a young patient with metastatic gastroesophageal cancer
🔬Poorly-diff adenoca, signet-ring cells, pMMR, HER2-, CPS 0
Most of us would have recommended FOLFOX
